Option chain shows key data for 808 Renewable Energy's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for 808 Renewable Energy.

808 Renewable Energy (OTC:RNWR) Stock, Option Chain

808 Renewable Energy Corp through its subsidiary engaged in the design, development, manufacturing, distribution, and marketing of reverse trikes and gyrocopters. It operates in two divisions, Aviation, and Reverse Trike. Its current product lines are AR-1 gyrocopter and electric reverse-trike vehicles.

News

Penny Stocks

Contracts

EZGO

RNWR

EZGO Technologies Secures First Export Order From SilverLight

Movers

Trading Ideas

EZGO Technologies To Co-Manufacture Reverse Trike Vehicles With SilverLight

808 RENEWABLE ENERGY CORP by 808 Renewable Energy Corp.

808 Renewable Energy Corp

<p>Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) is looking for Q4 GAAP EPS of $1.17-1.26 vs $1.25 analyst estimate. sees sales of $451.000 million-460.000 million vs $454.66 million estimate.</p>


Guidance

BOOT

Boot Barn Holdings Sees Q4 GAAP EPS $1.17-1.26 vs $1.25 Est; Sees Sales $451.000M-460.000M vs $454.66M Est

VIAV

VIAVI Expects Q3 Net Revenue Of $276M - $288M (Est $255.53M) And Adj EPS Of $0.10 - $0.13 (Est $0.09)

<p><strong>SkyWest</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>SkyWest beat estimated earnings by 28.999999999999996%, reporting an EPS of $2.34 versus an estimate of $1.81.</p>
<p>Revenue was up $192.62 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.24 which was followed by a 6.0% increase in the share price the next day.</p>
<p>Here's a look at SkyWest's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.92</td>
<td>1.73</td>
<td>1.23</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.16</td>
<td>1.82</td>
<td>1.45</td>
<td>0.42</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>889.00M</td>
<td>826.62M</td>
<td>800.15M</td>
<td>758.49M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>912.79M</td>
<td>867.12M</td>
<td>803.61M</td>
<td>751.79M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for SkyWest <a href="https://www.benzinga.com/quote/SKYW/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

SKYW

SkyWest Earnings Analysis: Q4 Recap

<p><strong>KORU Medical Systems (NASDAQ:</strong><a href="https://www.benzinga.com/stock/KRMD#NASDAQ"><strong>KRMD</strong></a><strong>) ("KORU Medical" or the "Company")</strong>, a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer on a Phase III clinical trial for an expanded indication of a commercialized drug therapy. The expanded indication is intended to treat a rare renal disorder in a population of approximately 30,000 patients with a projected 300,000 annual infusions.</p>
<p>This announcement highlights an additional collaboration between KORU Medical and its partners in the development of novel therapies and enhanced drug delivery experiences for patients living with rare conditions. The Phase III trial aims to assess the safety, efficacy, and performance of the drug to treat patients with complications from kidney transplants.</p>


Biotech

General

KRMD

KORU Medical Announces Collaboration With A Global Pharmaceutical Manufacturer For Phase III Trial On Renal Disorder, Targeting 30K Patients With 300K Annual Infusions; Focusing On Drug Safety, Efficacy, And Performance For Kidney Transplant Complications

<p><strong>AppFolio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) just disclosed its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>AppFolio missed estimated earnings by -2.0%, reporting an EPS of $0.92 versus an estimate of $0.94.</p>
<p>Revenue was up $31.83 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>During the previous quarter, the company beat on EPS by $0.26, leading to a 11.0% increase share price change the next day.</p>
<p>Here's a look at AppFolio's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.03</td>
<td>0.96</td>
<td>0.89</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.29</td>
<td>1.12</td>
<td>1.05</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>199.10M</td>
<td>190.57M</td>
<td>178.69M</td>
<td>162.71M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>205.73M</td>
<td>197.38M</td>
<td>187.43M</td>
<td>171.83M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for AppFolio <a href="https://www.benzinga.com/quote/APPF/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


APPF

AppFolio: Q4 Earnings Insights

<p>Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) raises FY2025 GAAP EPS guidance from $5.30-5.60 to $5.81-5.90 vs $5.76 analyst estimate. Raises FY2025 sales outlook from $1.87 billion-1.91 billion to $1.91 billion-1.92 billion vs $1.91 billion estimate.</p>


Boot Barn Holdings Raises FY2025 GAAP EPS Guidance from $5.30-5.60 to $5.81-5.90 vs $5.76 Est; Raises FY2025 Sales Guidance from $1.87B-1.91B to $1.91B-1.92B vs $1.91B Est

<p><strong>Olin</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) just disclosed its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Olin beat estimated earnings by 325.0%, reporting an EPS of $0.09 versus an estimate of $-0.04.</p>
<p>Revenue was up $56.40 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>During the previous quarter, the company missed on EPS by $0.25, leading to a 8.0% drop share price change the next day.</p>
<p>Here's a look at Olin's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.04</td>
<td>0.70</td>
<td>0.38</td>
<td>0.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.21</td>
<td>0.62</td>
<td>0.40</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.57B</td>
<td>1.71B</td>
<td>1.65B</td>
<td>1.52B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.59B</td>
<td>1.64B</td>
<td>1.64B</td>
<td>1.61B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Olin <a href="https://www.benzinga.com/quote/OLN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Olin: Q4 Earnings Insights

<p>The Q4 earnings report for <strong>First Business Finl Servs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) was released on Thursday, January 30, 2025 at 04:00 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>First Business Finl Servs beat estimated earnings by 13.0%, reporting an EPS of $1.43 versus an estimate of $1.26.</p>
<p>Revenue was up $4.52 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.05 in the last quarter, resulting in a 4.0% drop share price change the following day.</p>
<p>Here's a look at First Business Finl Servs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.19</td>
<td>1.09</td>
<td>1.12</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.24</td>
<td>1.23</td>
<td>1.04</td>
<td>1.15</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>38.77M</td>
<td>37.25M</td>
<td>37.73M</td>
<td>37.47M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>38.07M</td>
<td>37.97M</td>
<td>36.28M</td>
<td>36.63M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for First Business Finl Servs <a href="https://www.benzinga.com/quote/FBIZ/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FBIZ

First Business Finl Servs Earnings Analysis: Q4 Recap

<p><strong>Atlassian</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) reported its Q2 earnings results on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Atlassian beat estimated earnings by 26.0%, reporting an EPS of $0.96 versus an estimate of $0.76.</p>
<p>Revenue was up $226.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.13 in the previous quarter, leading to a 19.0% increase share price change the next day.</p>
<p>Here's a look at Atlassian's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.64</td>
<td>0.61</td>
<td>0.62</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.77</td>
<td>0.66</td>
<td>0.89</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.15B</td>
<td>1.13B</td>
<td>1.10B</td>
<td>1.02B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.19B</td>
<td>1.13B</td>
<td>1.19B</td>
<td>1.06B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Atlassian <a href="https://www.benzinga.com/quote/TEAM/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TEAM

Earnings Breakdown: Atlassian Q2

<p>The earnings results for <strong>Gen Digital</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) for Q3 were made public on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Gen Digital beat estimated earnings by 2.0%, reporting an EPS of $0.56 versus an estimate of $0.55.</p>
<p>Revenue was up $35.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>In the previous quarter, the company missed on EPS by $0.0, resulting in a 8.0% increase change in the share price the following day.</p>
<p>Here's a look at Gen Digital's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.53</td>
<td>0.52</td>
<td>0.50</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.54</td>
<td>0.53</td>
<td>0.53</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>969.93M</td>
<td>965.06M</td>
<td>965.02M</td>
<td>956.20M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>974.00M</td>
<td>965.00M</td>
<td>967.00M</td>
<td>951.00M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Gen Digital management provided guidance for Q4 2025, expecting earnings between $0.57 and $0.59 per share.</p>
<p>To track all earnings releases for Gen Digital <a href="https://www.benzinga.com/quote/GEN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Gen Digital Q3 Earnings

<p><strong>Credit Acceptance</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) released its Q4 earnings on Thursday, January 30, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Credit Acceptance beat estimated earnings by 28.000000000000004%, reporting an EPS of $10.17 versus an estimate of $7.93.</p>
<p>Revenue was up $74.30 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company missed on EPS by $0.26 which was followed by a 8.0% drop in the share price the next day.</p>
<p>Here's a look at Credit Acceptance's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>9.05</td>
<td>8.91</td>
<td>8.35</td>
<td>5.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>8.79</td>
<td>10.29</td>
<td>9.28</td>
<td>10.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>545.89M</td>
<td>525.03M</td>
<td>455.76M</td>
<td>489.53M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>550.30M</td>
<td>538.20M</td>
<td>508.00M</td>
<td>491.60M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Credit Acceptance <a href="https://www.benzinga.com/quote/CACC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CACC

Credit Acceptance: Q4 Earnings Insights

<p><strong>Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) released its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Bancorp beat estimated earnings by 2.0%, reporting an EPS of $1.15 versus an estimate of $1.13.</p>
<p>Revenue was up $2.14 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company missed on EPS by $0.08 in the last quarter, resulting in a 14.000000000000002% drop share price change the following day.</p>
<p>Here's a look at Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>1.07</td>
<td>1.05</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.07</td>
<td>1.06</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>99.31M</td>
<td>96.41M</td>
<td>116.51M</td>
<td>90.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>93.73M</td>
<td>93.80M</td>
<td>94.42M</td>
<td>92.16M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Bancorp management provided guidance for FY 2025, expecting earnings between $5.25 and $5.25 per share.</p>
<p>To track all earnings releases for Bancorp <a href="https://www.benzinga.com/quote/TBBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TBBK

Recap: Bancorp Q4 Earnings

<p>The Q2 earnings report for <strong>Standex International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) was released on Thursday, January 30, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Standex International beat estimated earnings by 14.000000000000002%, reporting an EPS of $1.91 versus an estimate of $1.67.</p>
<p>Revenue was up $11.41 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>The company beat on EPS by $0.01 in the previous quarter, leading to a 4.0% increase share price change the next day.</p>
<p>Here's a look at Standex International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.70</td>
<td>1.72</td>
<td>1.67</td>
<td>1.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.71</td>
<td>1.76</td>
<td>1.75</td>
<td>1.78</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>181.39M</td>
<td>181.29M</td>
<td>180.14M</td>
<td>182.52M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>170.46M</td>
<td>180.19M</td>
<td>177.27M</td>
<td>178.40M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Standex International <a href="https://www.benzinga.com/quote/SXI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Standex International Q2 Earnings

<p>The Q4 earnings report for <strong>Weyerhaeuser</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) was released on Thursday, January 30, 2025 at 04:11 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Weyerhaeuser beat estimated earnings by 56.99999999999999%, reporting an EPS of $0.11 versus an estimate of $0.07.</p>
<p>Revenue was down $66.00 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.04, leading to a 1.0% drop share price change the next day.</p>
<p>Here's a look at Weyerhaeuser's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.01</td>
<td>0.21</td>
<td>0.15</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.05</td>
<td>0.21</td>
<td>0.16</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.68B</td>
<td>1.95B</td>
<td>1.85B</td>
<td>1.86B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.68B</td>
<td>1.94B</td>
<td>1.80B</td>
<td>1.77B</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for Weyerhaeuser <a href="https://www.benzinga.com/quote/WY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Weyerhaeuser Q4

<p>Ameris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $1.19 by 15.13 percent.</p>


Earnings Beats

ABCB

Ameris Q4 2024 GAAP EPS $1.37 Beats $1.19 Estimate

<p><strong>Canadian National Railway</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) released its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Canadian National Railway missed estimated earnings by -3.0%, reporting an EPS of $1.3 versus an estimate of $1.34.</p>
<p>Revenue was down $169.00 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.03 in the last quarter, resulting in a 0.0% increase share price change the following day.</p>
<p>Here's a look at Canadian National Railway's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.23</td>
<td>1.41</td>
<td>1.25</td>
<td>1.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.26</td>
<td>1.35</td>
<td>1.28</td>
<td>1.48</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.98B</td>
<td>3.21B</td>
<td>3.10B</td>
<td>3.23B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.01B</td>
<td>3.16B</td>
<td>3.15B</td>
<td>3.29B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Canadian National Railway <a href="https://www.benzinga.com/quote/CNI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Canadian National Railway Earnings Analysis: Q4 Recap

<p><strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) just disclosed its Q4 earnings on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.12 in the previous quarter, leading to a 4.0% drop share price change the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Eastman Chemical Earnings Analysis: Q4 Recap

<p>The earnings results for <strong>Viavi Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) for Q2 were made public on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Viavi Solutions beat estimated earnings by 30.0%, reporting an EPS of $0.13 versus an estimate of $0.1.</p>
<p>Revenue was up $16.30 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 7.000000000000001% increase in the share price the next day.</p>
<p>Here's a look at Viavi Solutions's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>0.07</td>
<td>0.07</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.06</td>
<td>0.08</td>
<td>0.06</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>240.10M</td>
<td>250.82M</td>
<td>249.08M</td>
<td>251.00M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>238.20M</td>
<td>252.00M</td>
<td>246.00M</td>
<td>254.50M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Viavi Solutions management provided guidance for Q3 2025, expecting earnings between $0.1 and $0.13 per share.</p>
<p>To track all earnings releases for Viavi Solutions <a href="https://www.benzinga.com/quote/VIAV/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Viavi Solutions Q2 Earnings

<p><strong>Arthur J. Gallagher</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Arthur J. Gallagher beat estimated earnings by 5.0%, reporting an EPS of $2.13 versus an estimate of $2.03.</p>
<p>Revenue was up $284.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company missed on EPS by $0.01 in the last quarter, resulting in a 2.0% drop share price change the following day.</p>
<p>Here's a look at Arthur J. Gallagher's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.27</td>
<td>2.24</td>
<td>3.41</td>
<td>1.85</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.26</td>
<td>3.49</td>
<td>1.85</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.78B</td>
<td>2.76B</td>
<td>3.18B</td>
<td>2.36B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.81B</td>
<td>2.77B</td>
<td>3.26B</td>
<td>2.43B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Arthur J. Gallagher <a href="https://www.benzinga.com/quote/AJG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Arthur J. Gallagher: Q4 Earnings Insights

<p>The earnings results for <strong>Adtalem Glb Education</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) for Q2 were made public on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Adtalem Glb Education beat estimated earnings by 32.0%, reporting an EPS of $1.81 versus an estimate of $1.37.</p>
<p>Revenue was up $54.49 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company beat on EPS by $0.16 which was followed by a 10.0% increase in the share price the next day.</p>
<p>Here's a look at Adtalem Glb Education's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.13</td>
<td>1.28</td>
<td>1.16</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.29</td>
<td>1.37</td>
<td>1.50</td>
<td>1.23</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>397.70M</td>
<td>398.63M</td>
<td>391.70M</td>
<td>372.79M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>417.40M</td>
<td>409.91M</td>
<td>412.66M</td>
<td>393.24M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Adtalem Glb Education <a href="https://www.benzinga.com/quote/ATGE/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Adtalem Global Education Inc. Common Stock

Comments

808 Renewable Energy

808 Renewable Energy (RNWR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga